Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 6 participants, all of whom received a treatment called ranibizumab, given as an injection into the eye. The trial was measuring changes in vision over 12 months in people with a particular eye condition. Five of the six participants completed the study, and one did not finish. The main thing the trial was measuring was how much participants' vision changed over 12 months, using a standard eye chart test called the ETDRS chart (a chart used to measure how many letters a person can read correctly). The reported data shows that, on average, participants were able to read 12.2 more letters on the chart at 12 months compared to when they started the trial. The trial also set out to measure a number of other things — including the proportion of participants whose vision improved by 15 letters or more, changes in the thickness of a part of the eye called the fovea, and any unwanted events that occurred — however, no numerical results for these secondary measures were reported in the ClinicalTrials.gov data. It is worth noting that this was a very small trial with only 6 participants, and the secondary outcome data was not reported, so the picture of what was measured is incomplete. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 1 Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be able to give written consent and participate in all study visits for the full length of the study
- You must be over 18 years old
- The eye being studied must have uveitis (eye inflammation) that is not caused by an infection
- Your uveitis treatment must have been stable for at least one month before the injection, with the inflammation considered under control by the doctor
- Vision in the eye being studied must be 20/40 or worse
- A special eye scan called a fluorescein angiogram must show a specific type of swelling in the central part of your eye (cystoid macular edema)
- Another type of eye scan (OCT) must show that the central part of your retina is thicker than 300 microns
- Your eyes must be clear enough, and your pupils able to dilate enough, to allow the required eye scans and photos to be taken
Who may not be able to join:
- You received a steroid injection (triamcinolone) into the study eye within the past 3 months
- You are currently using more than two glaucoma medications for the study eye
- You have a significant scar-like membrane on your retina, as judged by your doctor
- Your eye scan shows a pulling force between the gel inside your eye and your retina (confirm with trial site)
- You have previously had surgery to remove the gel inside the study eye (vitrectomy)
- You are pregnant or breastfeeding
- You are a woman who could become pregnant and are not using an approved form of contraception (such as birth control pills, barrier methods with spermicide, an IUD, a hormone implant or patch, or surgical sterilization)
- You have any other condition the doctor believes would make it unsafe for you to receive the study treatment
- You are currently taking part in another clinical drug trial
- You received certain eye injections (Lucentis, Macugen, or Avastin) in the study eye within the past 6 weeks
- The inflammation in your study eye is not currently under control
- You currently have bleeding inside the gel of your eye
- You have an active eye infection (in either eye) affecting the surface or inside of the eye
- You have a known allergy to any ingredient in the study drug
- The pressure inside your study eye is above 25 mmHg even with glaucoma treatment
- Your blood pressure is above 180/110, unless it can be brought below that level with medication
- You have major non-eye surgery planned in the next 6 months
- You are unwilling or unable to follow all study-related procedures
- You are not willing to avoid using Avastin in the non-study eye during the trial period
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change From Baseline in Early Treatment Diabetic Retinopathy Study (ETDRS at 4 Meters) at 12 Months.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.